Literature DB >> 17366031

Drug resistance of Mycobacterium tuberculosis in the Sunamganj District of Bangladesh.

Dag Gundersen Storla1, Zeaur Rahim, Mohammed Akramul Islam, Steven Plettner, Vikarunessa Begum, Bjørn Myrvang, Gunnar Bjune, Elisabet Rønnild, Ulf R Dahle, Turid Mannsåker.   

Abstract

Spread of drug-resistant tuberculosis (TB) threatens TB-control programmes, and all countries need to monitor the patterns and trends of anti-TB drug resistance. Such data assess the quality of control programmes and help forecast future trends of drug resistance. It will also help to establish guidelines for TB therapy. The aim of the current study was to describe the rate of drug-resistant Mycobacterium tuberculosis in the Sunamganj District of Bangladesh. Bacterial isolates were collected from sputum smear positive (ss+) patients who attended the National TB Programme from November 2003 to December 2004. A total of 95 isolates was tested for susceptibility to streptomycin (SM), isoniazid (INH), rifampicin (RMP) and ethambutol (EMB) at the National Reference Laboratory for Mycobacteria at the Norwegian Institute of Public Health (NIPH), Oslo. The total resistance among new cases to any drug was 31%. For SM it was 18%, INH 23%, RMP 2%, EMB 10% and 2% were multidrug-resistant (MDR). The National Tuberculosis Programme (NTP) in Sunamganj is still effective, although the high resistance to INH is alarming. An increased risk of treatment failure has been demonstrated in areas with high levels of INH resistance, and a high proportion of INH resistant cases may develop resistance to RMP during treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17366031     DOI: 10.1080/00365540600951242

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  1 in total

1.  Identification of Mycobacterium tuberculosis clinical isolates in Bangladesh by a species distinguishable multiplex PCR.

Authors:  Chie Nakajima; Zeaur Rahim; Yukari Fukushima; Isamu Sugawara; Adri G M van der Zanden; Aki Tamaru; Yasuhiko Suzuki
Journal:  BMC Infect Dis       Date:  2010-05-15       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.